Does the media prefer SNDX or MNPR?

In the previous week, Monopar Therapeutics had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 5 mentions for Monopar Therapeutics and 2 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.43 beat Monopar Therapeutics' score of 0.62 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, MNPR or SION?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A Sionna Therapeutics N/A N/A -$75.27M -$1.93 N/A

Is MNPR or SION more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Sionna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Sionna Therapeutics N/A -27.31% -25.88%

Does the media prefer MNPR or SION?

In the previous week, Monopar Therapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 5 mentions for Monopar Therapeutics and 2 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.94 beat Monopar Therapeutics' score of 0.62 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MNPR or SEPN?

In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 5 articles in the media. Monopar Therapeutics' average media sentiment score of 0.62 beat Septerna's score of 0.40 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, AAPG or MNPR?

Monopar Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 20.03 -$177.71M N/A N/A Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A

Is AAPG or MNPR more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Monopar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Monopar Therapeutics N/A -12.84% -12.57%

Does the media refer more to ABCL or MNPR?

In the previous week, Monopar Therapeutics had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Monopar Therapeutics and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.91 beat Monopar Therapeutics' score of 0.62 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Monopar Therapeutics (MNPR) Competitors

$89.39 +1.71 (+1.95%)

As of 11:02 AM Eastern

Compare

MNPR vs. SNDX, SION, SEPN, AAPG, and ABCL

Should you buy Monopar Therapeutics stock or one of its competitors? MarketBeat compares Monopar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Monopar Therapeutics include Syndax Pharmaceuticals (SNDX), Sionna Therapeutics (SION), Septerna (SEPN), Ascentage Pharma Group International (AAPG), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.

How does Monopar Therapeutics compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Syndax Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

In the previous week, Monopar Therapeutics had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 5 mentions for Monopar Therapeutics and 2 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.43 beat Monopar Therapeutics' score of 0.62 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Monopar Therapeutics' return on equity of -12.84% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Monopar Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$217.17M	8.60	-$285.42M	-$2.79	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Syndax Pharmaceuticals currently has a consensus target price of $42.55, suggesting a potential upside of 101.83%. Monopar Therapeutics has a consensus target price of $107.67, suggesting a potential upside of 20.44%. Given Syndax Pharmaceuticals' higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

1.8% of Monopar Therapeutics shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Monopar Therapeutics beats Syndax Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Sionna Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Monopar Therapeutics' return on equity of -12.84% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Sionna Therapeutics	N/A	-27.31%	-25.88%

1.8% of Monopar Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Monopar Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Monopar Therapeutics currently has a consensus price target of $107.67, indicating a potential upside of 20.44%. Sionna Therapeutics has a consensus price target of $53.22, indicating a potential upside of 23.26%. Given Sionna Therapeutics' higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

In the previous week, Monopar Therapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 5 mentions for Monopar Therapeutics and 2 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.94 beat Monopar Therapeutics' score of 0.62 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Monopar Therapeutics beats Sionna Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Monopar Therapeutics compare to Septerna?

Monopar Therapeutics (NASDAQ:MNPR) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

1.8% of Monopar Therapeutics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 5.8% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Monopar Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Septerna has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market.

In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 5 articles in the media. Monopar Therapeutics' average media sentiment score of 0.62 beat Septerna's score of 0.40 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics presently has a consensus target price of $107.67, indicating a potential upside of 20.44%. Septerna has a consensus target price of $45.78, indicating a potential upside of 37.64%. Given Septerna's higher probable upside, analysts plainly believe Septerna is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Monopar Therapeutics has higher earnings, but lower revenue than Septerna. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Septerna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Septerna	$45.95M	32.63	-$48.88M	-$0.81	N/A

Monopar Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Septerna	-49.88%	-12.72%	-8.87%

Summary

Monopar Therapeutics and Septerna tied by winning 7 of the 14 factors compared between the two stocks.

How does Monopar Therapeutics compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

In the previous week, Monopar Therapeutics had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 5 mentions for Monopar Therapeutics and 4 mentions for Ascentage Pharma Group International. Monopar Therapeutics' average media sentiment score of 0.62 beat Ascentage Pharma Group International's score of 0.31 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Ascentage Pharma Group International's return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Monopar Therapeutics	N/A	-12.84%	-12.57%

Ascentage Pharma Group International presently has a consensus target price of $46.43, indicating a potential upside of 163.72%. Monopar Therapeutics has a consensus target price of $107.67, indicating a potential upside of 20.44%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ascentage Pharma Group International is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

1.8% of Monopar Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Monopar Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	20.03	-$177.71M	N/A	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Summary

Monopar Therapeutics beats Ascentage Pharma Group International on 7 of the 12 factors compared between the two stocks.

How does Monopar Therapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Monopar Therapeutics (NASDAQ:MNPR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AbCellera Biologics has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Monopar Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	33.19	-$146.41M	-$0.48	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

In the previous week, Monopar Therapeutics had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Monopar Therapeutics and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.91 beat Monopar Therapeutics' score of 0.62 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. Monopar Therapeutics' return on equity of -12.84% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Monopar Therapeutics	N/A	-12.84%	-12.57%

AbCellera Biologics currently has a consensus price target of $7.80, suggesting a potential downside of 4.48%. Monopar Therapeutics has a consensus price target of $107.67, suggesting a potential upside of 20.44%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Monopar Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Monopar Therapeutics beats AbCellera Biologics on 9 of the 16 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNPR vs. The Competition

Export

Metric	Monopar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$599.28M	$3.64B	$6.85B	$12.33B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-47.08	21.42	25.86	24.20
Price / Sales	N/A	341.79	550.66	101.54
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	4.34	8.44	10.89	6.42
Net Income	-$13.72M	$23.92M	$3.58B	$336.87M
7 Day Performance	30.20%	2.92%	2.51%	0.94%
1 Month Performance	37.44%	0.52%	0.22%	-0.53%
1 Year Performance	166.05%	66.92%	35.34%	27.96%

Monopar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNPR Monopar Therapeutics	1.8172 of 5 stars	$89.39 +2.0%	$107.67 +20.4%	+161.0%	$599.28M	N/A	N/A	10	Analyst Upgrade
SNDX Syndax Pharmaceuticals	3.1483 of 5 stars	$18.55 +0.4%	$42.55 +129.4%	+135.7%	$1.64B	$172.35M	N/A	110	Positive News Gap Down
SION Sionna Therapeutics	2.5265 of 5 stars	$34.75 -3.5%	$53.22 +53.2%	+166.3%	$1.63B	N/A	N/A	35
SEPN Septerna	2.3201 of 5 stars	$35.17 -2.4%	$45.78 +30.2%	+255.3%	$1.62B	$45.95M	N/A	N/A	Gap Down
AAPG Ascentage Pharma Group International	4.6805 of 5 stars	$17.01 -1.9%	$46.43 +172.9%	-57.7%	$1.62B	$82.10M	N/A	600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNPR) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monopar Therapeutics (MNPR) Competitors

MNPR vs. SNDX, SION, SEPN, AAPG, and ABCL

How does Monopar Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does Monopar Therapeutics compare to Sionna Therapeutics?

Summary

How does Monopar Therapeutics compare to Septerna?

Summary

How does Monopar Therapeutics compare to Ascentage Pharma Group International?

Summary

How does Monopar Therapeutics compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monopar Therapeutics (MNPR) Competitors

MNPR vs. SNDX, SION, SEPN, AAPG, and ABCL

How does Monopar Therapeutics compare to Syndax Pharmaceuticals?

Which has more volatility and risk, SNDX or MNPR?

Does the media prefer SNDX or MNPR?

Is SNDX or MNPR more profitable?

Which has better earnings and valuation, SNDX or MNPR?

Do analysts recommend SNDX or MNPR?

Do insiders & institutionals hold more shares of SNDX or MNPR?

Summary

How does Monopar Therapeutics compare to Sionna Therapeutics?

Is MNPR or SION more profitable?

Do institutionals & insiders believe in MNPR or SION?

Which has more risk and volatility, MNPR or SION?

Do analysts recommend MNPR or SION?

Which has stronger valuation & earnings, MNPR or SION?

Does the media prefer MNPR or SION?

Summary

How does Monopar Therapeutics compare to Septerna?

Do institutionals & insiders have more ownership in MNPR or SEPN?

Which has more risk and volatility, MNPR or SEPN?

Does the media prefer MNPR or SEPN?

Do analysts recommend MNPR or SEPN?

Which has stronger valuation & earnings, MNPR or SEPN?

Is MNPR or SEPN more profitable?

Summary

How does Monopar Therapeutics compare to Ascentage Pharma Group International?

Does the media favor AAPG or MNPR?

Which has more risk and volatility, AAPG or MNPR?

Is AAPG or MNPR more profitable?

Do analysts recommend AAPG or MNPR?

Do institutionals & insiders believe in AAPG or MNPR?

Which has preferable earnings and valuation, AAPG or MNPR?

Summary

How does Monopar Therapeutics compare to AbCellera Biologics?

Do institutionals and insiders have more ownership in ABCL or MNPR?

Which has more volatility & risk, ABCL or MNPR?

Which has better valuation & earnings, ABCL or MNPR?

Does the media refer more to ABCL or MNPR?

Is ABCL or MNPR more profitable?

Do analysts recommend ABCL or MNPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools